The Canadian multi-ethnic research on aging (CAMERA) study:
Study design and participant characteristics

Tulip Marawi[1,2], Harleen Rai[1], Rohina Kumar[1], Katie L. Vandeloo[1,2], Rachel Yep[1], Silina Z. Boshmaf[1], Angelina Zhang[1], Georgia Gopinath[1], Sarah-Mei Chen[1], Simran Malhotra[1], Alexander J. Nyman[1], Madeline Wood Alexander[1,3], Tallinn Splinter[1,3], Lucas Xavier Perri[1], Douglas P. Munoz[4,5], Walter Swardfager[1,6], Jennifer D. Ryan[7], Sandra E. Black[1,8], Maged Goubran,*[1,9,10] Jennifer S. Rabin*[1,2,3,8,9]

1. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada
2. Graduate Department of Psychological Clinical Science, University of Toronto Scarborough, Toronto, ON, Canada
3. Rehabilitation Sciences Institute, University of Toronto, Toronto, ON, Canada
4. Department of Biomedical & Molecular Sciences, Queen's University, Kingston, Canada
5. The Centre for Neuroscience Studies, Kingston Health Sciences Centre; Division of Neurology, Department of Medicine, Queen's University, Kingston, Canada
6. Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada
7. Rotman Research Institute, Baycrest Health Sciences, Toronto ON, Canada
8. Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
9. Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, Canada
10. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

Corresponding Author: Jennifer S. Rabin, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Room M6-178, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. Email: jennifer.rabin@sri.utoronto.ca

*Co-senior authors

Abstract

INTRODUCTION: Asian Americans and Canadians are among the fastest growing ethnoracial groups yet remain underrepresented in Alzheimer's disease and related dementias (ADRD) research. To address this gap, we launched the CAnadian Multi-Ethnic Research on Aging (CAMERA) study.

METHODS: CAMERA is a longitudinal, observational study based in Toronto, Canada. The study is enrolling 300 adults aged 55-85 who self-identify as South Asian, Chinese, or non-Hispanic White. At baseline (Year 1), Year 3, and Year 5, participants complete clinical assessments, brain MRI, cognitive testing, and blood-based biomarker collection. Annually, participants complete questionnaires capturing demographic, health, mood, sleep, physical activity, quality of life, community/sociocultural factors, cognitive concerns, and sex-specific health.

RESULTS: We present baseline data on ethnoracial differences on demographic and clinical variables from 200 participants.

DISCUSSION: CAMERA will yield unavailable data on risk and protective factors for dementia in Asian subgroups, guiding the development of culturally tailored strategies to prevent and delay ADRD in Asian populations.

Keywords: Alzheimer's disease and related dementias, risk and protective factors, South Asian and Chinese populations, culturally neutral cognitive testing, ethnoracial diversity

1.0 Background

Alzheimer's disease (AD) and related dementias (ADRD) are among the most pressing public health challenges of our time, with profound personal, societal, and economic consequences.[1] Despite this, most research has focused on predominantly White cohorts, leaving critical knowledge gaps in our understanding of how these conditions impact racially and ethnically diverse populations.[2–7] This knowledge gap is especially pronounced among individuals of Asian descent.[2,8–10] For example, in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set only 2.6% of participants are of Asian ancestry[11] despite the fact that nearly 14% of U.S. older adults are of Asian descent.[12] Similarly, a comprehensive review of 719 neuroimaging studies on AD found that 89% of participants were White, with no representation of Asian individuals.[6]

Beyond underrepresentation, the problem is compounded by the common practice of collapsing distinct Asian subpopulations, such as individuals of South Asian and Chinese descent, into a single, monolithic "Asian" category in demographic reporting and ethnically stratified analyses.[13] This reductive approach masks meaningful heterogeneity across factors such as socioeconomic status, dietary practices, experiences of racism and discrimination, access to culturally competent healthcare, and traditional health beliefs, which may influence dementia risk.[14,15] In turn, this lack of granularity constrains the development of effective, culturally tailored strategies for prevention, diagnosis, and treatment that address the distinct needs of specific Asian subgroups.[7,16]

Although epidemiological data on dementia incidence among Asian subgroups remain limited, existing evidence suggests meaningful differences in risk. For example, South Asian individuals in the United States appear to have a higher incidence of dementia than Chinese

individuals and other ethnoracial groups,[17] particularly when diabetes is present.[18] Vascular burden, a well-established risk factor for dementia, may be a key driver of these disparities.[19,20] Studies from Canadian populations indicate that South Asian and Chinese individuals exhibit markedly different vascular profiles: [21,22] South Asian individuals tend to have a higher vascular burden compared to both White and Chinese individuals, whereas Chinese individuals tend to have a lower vascular burden compared to both groups.[21–24] These distinct vascular profiles may underlie differences in ADRD risk, with South Asians facing elevated risk due to higher vascular burden and Chinese individuals potentially at lower risk. However, this question has never been systematically examined.

To address these critical gaps, we launched the CAnadian Multi-Ethnic Research on Aging (CAMERA) study, a longitudinal observational study that uses a deep phenotyping approach to identify risk and protective factors for ADRD among underrepresented South Asian and Chinese individuals. A non-Hispanic White comparison group was included to contextualize ethnic differences against a widely studied reference group. Every other year, CAMERA participants complete a set of assessments that include clinical evaluations, brain MRI, a blood-draw, questionnaires, and both standard and novel cognitive tests designed to be language- and culturally neutral. By addressing this longstanding gap, this study will generate critical insights into the mechanisms of ADRD risk and resilience and provide the foundation for developing culturally informed strategies for prevention and intervention in historically overlooked communities.

2.0 Methods

The CAMERA study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre in Toronto, Canada.

2.1 Participants

The CAMERA study is currently enrolling 300 adults between the ages 55 and 85 who self-identify as South Asian, Chinese, or non-Hispanic White (100 participants per group). Inclusion criteria are as follows: (1) sufficient self-reported English fluency to provide informed consent and understand testing instructions (assessed using a Likert scale); 2) at least 8 years of formal education; 3) A global Clinical Dementia Rating (CDR)[25] of 0 (clinically normal) or 0.5 (mild cognitive difficulties) at baseline; 4) adequate (or corrected vision) and hearing to participate in cognitive testing; and 5) availability of a study partner who knows the participant well, maintains at least weekly contact, and can provide informed observations about their cognition.

Exclusion criteria include: 1) history of major cardio/cerebrovascular event (e.g., myocardial infarction, symptomatic stroke); 2) presence of unstable medical conditions (e.g., pulmonary or endocrine disorders); 3) active infectious diseases; 4) current diagnosis of major psychiatric disorders, neurological disorders, or dementia; 5) history of a significant learning disability; 6) history of a significant head trauma or recurrent concussions with loss of consciousness or hospitalization; 7) pain or sleep disorders that could interfere with cognitive testing; 8) recent history of substance or drug abuse; 8) medical conditions that may obscure relevant relationships (e.g., active cancer); and 9) MRI contraindications.

2.2 Study Design

Participants complete in-person assessments at baseline (Year 1), Year 3 and Year 5. Each in-person assessment involves two in-person study visits scheduled within a 2-month window. These visits involve comprehensive clinical assessments (vital signs, anthropometric measures, gait assessment, hearing test), brain MRI, a blood draw, cognitive testing (including

eye tracking tasks), as well as questionnaires. Questionnaires may be completed on-site or remotely via REDCap. At the end of the first visit, participants are provided with an actigraphy device to wear for 10 consecutive days to monitor physical activity and sleep patterns, after which the device is returned by mail. During the intervening years (Years 2 and 4), participants complete follow-up questionnaires remotely via REDCap (**Figure 1**).

2.3 Study Measures

2.3.1 Clinical assessments

Clinical Dementia Rating (CDR)

Participants and their study partners complete the CDR[25], which is administered by trained personnel at baseline (Year 1), Year 3, and Year 5.

Vital Signs

Blood pressure and heart rate are measured using an automated sphygmomanometer. Six readings (three seated and three standing) are taken one minute apart. Respiration rate, waist circumference, hip circumference, height, and weight are also collected.

Gait Assessment

Gait is measured using a pressure-sensitive walkway (GaitRite)[26] that records the timing and placement of each step using protocols from the Ontario Neurodegenerative Disease Research Initiative (ONDRI).[27,28] Gait performance is assessed under both single-task (preferred and fast walking) and cognitively demanding dual-task conditions. There are three dual-tasks: 1) counting backwards from 100 by ones; 2) counting backwards from 100 by sevens; and 3) naming as many different animals as possible.

Participants complete a hearing assessment using the Triple Digit Test.[29,30] In this task, participants are instructed to listen to a voice recording in which three digits are presented orally against background noise. They are then asked to report the numbers they heard in the correct order.

2.3.2 Brain Magnetic Resonance Imaging (MRI)

Brain MRI scans are acquired on a 3T Siemens MAGNETOM Prisma magnetic resonance system, using a 64-channel head coil. Each 50-minute scanning session includes the following sequences (see **Supplemental Table 1** for more details): 1) 3-dimensional T1-weighted magnetization prepared rapid gradient echo (MPRAGE) acquired in the sagittal plane; 2) 3-dimensional T2-weighted Sampling Perfection with Application optimized Contrast using different flip angle Evolution (SPACE) acquired in the axial plane; 3) 3-dimensional T2-weighted Fluid-Attenuated Inversion Recovery (FLAIR) acquired in the sagittal plane; 4) resting-state functional MRI (rs-fMRI) acquired in two phase-encoding (PE) directions (anterior-to-posterior, and posterior-to-anterior); 5) multi-shell diffusion weighted imaging (DWI) acquired with 95 diffusion directions in two PE directions (anterior to posterior ($b=2000s/mm^2$, $b=1000s/mm^2$) and posterior-to- anterior ($b=0s/mm^2$) for distortion correction); 6) a high-resolution T2-weighted turbo spin echo (TSE) hippocampal scan, oblique to the long axis of the hippocampus; 7) pseudo-continuous arterial spin labeling (ASL); and 8) susceptibility weighted imaging (SWI).

2.3.3 Cognitive assessments

Eye-tracking

A major barrier to conducting ADRD research in diverse ethnoracial groups is that most cognitive tests were developed and validated in English-speaking White individuals born in Western countries. As a result, their validity may be compromised when administered to adults from different linguistic and cultural backgrounds.[31,32] Current strategies to address this limitation include translating existing tests, developing group-specific norms, and/or using an interpreter to conduct neuropsychological testing.[33,34] However, these approaches are resource-intensive and may not fully eliminate biases. An alternative approach employed in the CAMERA study is to use tests that minimize language demands and cultural influences, allowing the same battery of tests to be applied uniformly across ethnoracial groups. To achieve this, we are using eye-tracking tasks, a widely accepted method for assessing cognition that has been applied in non-human primates,[35–37] infants,[38–40] and adults with aphasia or speech limitations.[41,42] Eye tracking tasks are particularly advantageous because they: (1) can be adapted to avoid language-dependent and culturally biased stimuli, and (2) do not require verbal responses, making them especially well-suited for participants from diverse linguistic backgrounds.

The CAMERA study employs two well-validated eye-tracking tasks: the Interleaved Pro/Anti-Saccade Task (IPAST)[43,44] and the Visual Paired Comparison Task (VPCT).[45] The IPAST provides measures of processing speed and executive function, whereas the VPCT provides a measure of episodic memory.

In the IPAST, participants are instructed to either look toward a peripheral visual stimulus (automatic pro-saccade) or to instead inhibit this response and look in the opposite direction (voluntary anti-saccade)[43,44] (**Figure 2A**). Saccadic reaction time on pro-saccade trials

provides a measure of processing speed through sensory-motor pathways, whereas saccadic reaction time and direction errors on anti-saccade trials provide measures of executive function.[43,44,46] Previous studies have shown that both pro- and anti-saccade performance declines with increasing age[47–49], and anti-saccade performance is impaired in mild cognitive impairment and dementia.[50,51]

The VPCT task begins with a familiarization phase in which participants are presented with a series of pairs of identical abstract images[45] (**Figure 2B**). During the test phase, participants are presented with a new series of image pairs. In each trial, one is an 'old' image from the familiarization phase and the other is a 'novel' image not previously seen.[45,52] Based on the well-established novelty effect[53,54], participants with intact memory should spend more time looking at the novel image compared to the old image (i.e., novelty preference). Prior work has demonstrated that novelty preference on the VPCT declines with age[52], is impaired in mild cognitive impairment[53], and predicts progression to AD dementia.[55,56]

Standard Neuropsychological Tests

In addition to eye-tracking tasks, study participants complete a battery of standardized neuropsychological tests that assess processing speed, executive function, episodic memory, language, and visuospatial abilities (**Table 1**). The battery includes both paper-based and computer-based assessments. The battery of tests was designed to minimize language demands and culturally specific stimuli, thereby increasing their cross-cultural applicability. However, a subset of language-based measures was included to facilitate comparison with existing literature, despite the potential for cultural and linguistic bias in these assessments.

2.3.4 Questionnaires

Participants complete a series of questionnaires annually via REDCap (**Table 2**). The questionnaires capture a range of variables, including: 1) demographic information; 2) socioeconomic status; 3) immigration history; 4) linguistic background; 5) acculturation; 6) medical history; 7) vascular risk; 8) mental health; 9) physical activity; 10) sleep quality; 11) quality of life; 12) perceived discrimination; 13) environmental factors; 14) cognitive concerns; 15) functional status; and 16) sex-specific health questions.

2.3.5 Actigraphy

Participants are provided with a wearable wrist accelerometer (GENEActive) that continuously records daytime and nighttime activity, including sleep, physical activity, and sedentary time. They are asked to wear the accelerometer for 10 consecutive days.[57]

2.3.6 Blood Collection

Participants undergo a fasting venous blood draw. Blood samples are processed at Sunnybrook Health Sciences Centre, and analyzed to measure lipids (i.e., total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides), glucose levels (i.e., hemoglobin A1c (HbA1C)), and inflammation (i.e., C-reactive protein). Serum, plasma, and white blood cells samples are also stored for future analyses, including genetic profiling, as well as markers of AD, neurodegeneration, and inflammation.

2.4 Community-Based Participatory Research Approaches

The Community Advisory Board (CAB) for the CAMERA study was established to ensure that the research remains closely aligned with perspectives and needs of the communities it serves. The CAB currently includes five committed community members who share identities and lived experiences with the study participants, including two members identifying as South

Asian, two as Chinese, and one as non-Hispanic White. Notably, four of the five members are also participants in the study, providing them with firsthand knowledge of study procedures and enabling particularly informed and meaningful feedback.

The CAB convenes formally on a quarterly basis but also meets in smaller, ad hoc groups as needed. The CAB's primary role is to provide ongoing, community-driven feedback on all aspects of the CAMERA study. Their contributions include: 1) ensuring that the study objectives align with the perspectives of South Asian and Chinese communities; 2) assisting with community outreach; 3) providing feedback on study assessments and procedures to ensure they are culturally appropriate and relevant to the communities involved; and 4) assisting with dissemination of study findings in accessible and culturally appropriate ways.

2.5 Participation Benefits

A core value of the CAMERA study is our strong commitment to sharing individual level results with participants. These practices are designed to promote transparency, while fostering trust and engagement. We share three types of results with participants: 1) MRI results: Participants may request both their raw MRI data and the radiological report. If incidental findings are identified, referrals are coordinated within the hospital to ensure timely follow-up. 2) Cognitive test findings: Participants may request a feedback session with a neuropsychologist to review their cognitive results. If testing reveals previously unrecognized cognitive impairment, participants are informed directly and referred to a neurologist within the hospital; 3) Blood test results: Participants may request results from the standard blood panel (e.g., total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, glucose levels). If clinically significant results are identified, a nurse practitioner reviews the findings with the

participant and provides recommendations. With the participant's consent, these findings are also shared with their primary care physician.

2.6 Retention Strategies

We have implemented several strategies to promote participant engagement and retention First, as described above, participants receive their study results, a practice shown to motivate long-term study retention[58] and one that has been especially valued by our participants. Second, our team distributes quarterly newsletters that include: 1) study updates (e.g., recruitment milestones and findings from CAMERA); 2) highlights of recent advances in the field; and 3) educational content (e.g., tips for optimizing brain health). Third, we host *Cortex Conversations*, a community-focused webinar series that offers participants with accessible, expert-led discussions on dementia-related topics. Fourth, we offer small tokens of appreciation (e.g., holiday cards) to acknowledge and thank participants for their ongoing contribution.[59]

3.0 Results

Baseline demographic and clinical characteristics of the participant sample is summarized in **Table 3**. As of July 2025, 200 participants have completed the baseline (Year 1) study procedures. This includes 52 South Asian, 77 Chinese, and 71 non-Hispanic White participants. With respect to follow-up visits, 99 participants have completed the Year 2 remote questionnaires (33 South Asian, 34 Chinese, and 32 non-Hispanic White participants) and 46 participants have completed the Year 3 in-person follow-up assessments (17 South Asian, 16 Chinese, and 13 non-Hispanic White participants).

Age, sex, years of education, and annual income did not differ significantly across South Asian, Chinese, and non-Hispanic White participants. As expected, both South Asian and Chinese participants were significantly less likely to be born in Canada, and more likely to have

English as a second language compared to non-Hispanic White participants. South Asian participants immigrated at a significantly younger age than Chinese participants.

South Asian participants had significantly lower high-density lipoprotein (HDL) cholesterol and higher triglyceride levels compared to both Chinese and non-Hispanic White participants. Both South Asian and Chinese participants had higher blood glucose levels compared to non-Hispanic White participants. In contrast, Chinese participants had significantly lower body mass index compared to both South Asian and non-Hispanic White participants and endorsed lower quality of life compared to non-Hispanic White participants.

With respect to subjective cognitive concerns, both South Asian and Chinese participants endorsed significantly greater concerns on the Cognitive Function Index (CFI) compared to non-Hispanic White participants. Of note, this result remained consistent after excluding participants with a global CDR of 0.5.

There were no significant differences among ethnoracial groups in depressive or anxiety symptoms, cholesterol levels (total, low-density lipoprotein, non-HDL), blood pressure readings, or waist-to-hip ratio.

4.0 Discussion

Individuals of Asian descent, particularly South Asian and Chinese populations, represent one of the fastest growing ethnoracial groups in the United States[60] and Canada.[61] Despite this rapid growth, these communities remain significantly underrepresented in ADRD research.[8–10,62] To address this critical gap, we launched the CAMERA study, which applies a deep phenotyping approach to investigate risk and protective factors for dementia in individuals of South Asian and Chinese descent.

Here, we report preliminary demographic and clinical characteristics of the CAMERA cohort. No significant group differences were observed in age, sex, or years of education, with education levels being high (average 16 years), consistent with other observational cohort studies.[63,64] In contrast, vascular and cardiometabolic risk profiles differed by group. Consistent with prior studies[21,65,66], South Asian participants had less favourable vascular risk profiles compared to non-Hispanic White participants, including significantly lower HDL cholesterol, higher glucose, and higher triglyceride levels. While each of these risk factors has been linked to cognitive decline and dementia[67–69], their co-occurrence may have a compounding effect on risk[69,70]. Epidemiological studies further suggest that South Asians with conditions such as type 2 diabetes may face disproportionately higher dementia risk relative to other ethnoracial groups.[18]

In line with some[71], though not all previous studies[21], Chinese participants exhibited higher glucose levels compared to non-Hispanic White participants despite having significantly lower BMI. This paradox reflects prior evidence that Asian populations, including Chinese, may experience greater insulin resistance at lower BMI thresholds compared to White populations, highlighting the need for population-specific risk stratification.[72]

Interestingly, both South Asian and Chinese participants reported significantly greater cognitive concerns compared to White participants even when restricted to clinically normal individuals. This is consistent with prior findings from the A4 screening study, where the Asian cohort demonstrated higher CFI scores than all other groups, including non-Hispanic Black, Hispanic, and non-Hispanic White participants.[73] Importantly, the CFI has previously been shown to be invariant to race/ethnicity[74], supporting the view that these differences reflect true variation in subjective cognitive concerns rather than measurement bias. The underlying reasons remain unclear but will be investigated in future work.

To our knowledge, CAMERA is the only deep phenotyping study in North America focused specifically on South Asian and Chinese communities. The most comparable initiative is the Asian Cohort for Alzheimer's Disease (ACAD).[75] However, ACAD differs in important ways from CAMERA. Its primary emphasis is on genetics, and it does not include neuroimaging and only employs limited cognitive testing. Moreover, ACAD includes individuals of Chinese, Korean, and Vietnamese ancestry, but does not currently include South Asian individuals.

A key feature of CAMERA is the active involvement of community voices. Our CAB serves as a bridge between the research team, study participants, and the broader communities we aim to serve, ensuring that the study design, assessment practices, and dissemination are guided by community perspectives, cultural relevance, and inclusivity. This collaborative approach fosters mutual trust, improves study relevance and acceptability, and enhances the impact and reach of research findings within diverse populations.

Recruitment for CAMERA has been highly successful, driven from the outset by a commitment to valuing participants. A central part of this has been the return of individualized results, which participants describe as especially meaningful. They value access to MRI findings and cognitive testing, which are not typically available, and appreciate being monitored and informed over time. When incidental findings are identified, the team provides timely referrals, a practice that participants have expressed strong appreciation for. Similarly, when questionnaire responses reveal concerns such as depression or anxiety, mental health resources are offered, which participants view as a clear sign that their well-being is taken seriously. The presence of multilingual team members further enhances comfort and cultural sensitivity, even though testing is conducted in English. Collectively, these practices foster participants' sense of being cared for

and respected, strengthening trust and encouraging positive word-of-mouth within their communities.

In sum, CAMERA represents a critical step toward addressing the persistent underrepresentation of South Asian and Chinese communities in ADRD research. By combining deep phenotyping with neuroimaging, comprehensive cognitive testing, and culturally informed engagement strategies, CAMERA provides a unique platform to investigate population-specific risk and protective factors for dementia. As the cohort expands and longitudinal data accrue, CAMERA is well positioned to generate insights that will advance precision medicine approaches to dementia prevention and intervention, while also serving as a model for equitable and inclusive research across diverse populations.

References

1. 2025 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*. 2025;21(4):e70235. doi:10.1002/alz.70235

2. Babulal GM, Quiroz YT, Albensi BC, et al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. *Alzheimers Dement*. 2019;15(2):292-312. doi:10.1016/j.jalz.2018.09.009

3. Brewster P, Barnes L, Haan M, et al. Progress and future challenges in aging and diversity research in the United States. *Alzheimers Dement*. 2019;15(7):995-1003. doi:10.1016/j.jalz.2018.07.221

4. Brickman AM, Manly JJ, Honig LS, et al. Plasma p☐tau181, p☐tau217, and other blood☐based Alzheimer's disease biomarkers in a multi☐ethnic, community study. *Alzheimer's & Dementia*. 2021;17(8):1353-1364. doi:10.1002/alz.12301

5. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia*. 2024;20(8):5143-5169. doi:10.1002/alz.13859

6. Lim AC, Barnes LL, Weissberger GH, et al. Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review. *Commun Med*. 2023;3(1):101. doi:10.1038/s43856-023-00333-6

7. Zhu Y, Park S, Kolady R, et al. A systematic review/meta☐analysis of prevalence and incidence rates illustrates systemic underrepresentation of individuals racialized as Asian and/or Asian☐American in ADRD research. *Alzheimer's & Dementia*. 2024;20(6):4315-4330. doi:10.1002/alz.13820

8. Krishnan A, Waite LM, Stanaway FF. Representation of racial and ethnic minority groups in cohort studies evaluating risk factors for dementia: protocol for a scoping review. *BMJ Open*. 2021;11(5):e044404. doi:10.1136/bmjopen-2020-044404

9. Grill JD, Sperling RA, Raman R. What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials? *JAMA Neurol*. 2022;79(11):1097-1098. doi:10.1001/jamaneurol.2022.2274

10. Brewster P, Barnes L, Haan M, et al. Progress and future challenges in aging and diversity research in the United States. *Alzheimer's & Dementia*. 2019;15(7):995-1003. doi:10.1016/j.jalz.2018.07.221

11. Ho P, Yu WH, Tee BL, et al. Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non☐genetic risk factors for Alzheimer's disease among Asian Americans and Canadians. *Alzheimer's & Dementia*. 2024;20(3):2058-2071. doi:10.1002/alz.13611

12. United States Census Bureau. *Not All Racial and Ethnic Groups Are Aging At National Pace*.; 2024. https://www.census.gov/library/stories/2024/07/population-projections.html

13.   Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. *Alzheimer's & Dementia*. 2016;12(3):216-224. doi:10.1016/j.jalz.2015.12.007

14.   Yaffe K, Falvey C, Harris TB, et al. Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. *BMJ*. 2013;347(dec19 5):f7051-f7051. doi:10.1136/bmj.f7051

15.   Garcia MA, Saenz J, Downer B, Wong R. The role of education in the association between race/ethnicity/nativity, cognitive impairment, and dementia among older adults in the United States. *DemRes*. 2018;38:155-168. doi:10.4054/DemRes.2018.38.6

16.   Holland AT, Palaniappan LP. Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation. *Ann Epidemiol*. 2012;22(6):397-405. doi:10.1016/j.annepidem.2012.04.001

17.   Hayes-Larson E, Zhou Y, Wu Y, et al. Estimating dementia incidence in insured older Asian Americans and Pacific Islanders in California: an application of inverse odds of selection weights. *American Journal of Epidemiology*. Published online July 5, 2024:kwae182. doi:10.1093/aje/kwae182

18.   Hayes-Larson E, Zhou Y, Wu Y, et al. Heterogeneity in the effect of type 2 diabetes on dementia incidence in a diverse cohort of Asian American and non-Latino White older adults. *American Journal of Epidemiology*. 2024;193(9):1261-1270. doi:10.1093/aje/kwae051

19.   Rabin JS, Schultz AP, Hedden T, et al. Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. *JAMA Neurol*. 2018;75(9):1124. doi:10.1001/jamaneurol.2018.1123

20.   Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(6):710-717. doi:10.1016/j.jalz.2014.10.008

21.   Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). *Lancet*. 2000;356(9226):279-284. doi:10.1016/s0140-6736(00)02502-2

22.   Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. *Can J Cardiol*. 2011;27(2):e1-e33. doi:10.1016/j.cjca.2010.12.054

23.   Chiu M, Maclagan LC, Tu JV, Shah BR. Temporal trends in cardiovascular disease risk factors among white, South Asian, Chinese and black groups in Ontario, Canada, 2001 to 2012: a population-based study. *BMJ Open*. 2015;5(8):e007232. doi:10.1136/bmjopen-2014-007232

24.   Chiu M, Austin PC, Manuel DG, Tu JV. Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. *CMAJ*. 2010;182(8):E301-310. doi:10.1503/cmaj.091676

25.   Morris JC. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type. *Int Psychogeriatr*. 1997;9(S1):173-176. doi:10.1017/S1041610297004870

26.   Webster KE, Wittwer JE, Feller JA. Validity of the GAITRite® walkway system for the measurement of averaged and individual step parameters of gait. *Gait & Posture*. 2005;22(4):317-321. doi:10.1016/j.gaitpost.2004.10.005

27.   Farhan SMK, Bartha R, Black SE, et al. The Ontario Neurodegenerative Disease Research Initiative (ONDRI). *Can J Neurol Sci*. 2017;44(2):196-202. doi:10.1017/cjn.2016.415

28.   Sunderland KM, Beaton D, Arnott SR, et al. Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. *Alzheimer's & Dementia*. 2023;19(1):226-243. doi:10.1002/alz.12632

29.   Smits C, Kapteyn TS, Houtgast T. Development and validation of an automatic speech-in-noise screening test by telephone. *International Journal of Audiology*. 2004;43(1):15-28. doi:10.1080/14992020400050004

30.   Giguère C, Lagacé J, Ellaham NN, et al. Development of the Canadian Digit Triplet Test in English and French. *The Journal of the Acoustical Society of America*. 2020;147(3):EL252-EL258. doi:10.1121/10.0000825

31.   Manly JJ. Critical Issues in Cultural Neuropsychology: Profit from Diversity. *Neuropsychol Rev*. 2008;18(3):179-183. doi:10.1007/s11065-008-9068-8

32.   Vila-Castelar C, Fox-Fuller JT, Guzmán-Vélez E, Schoemaker D, Quiroz YT. A cultural approach to dementia — insights from US Latino and other minoritized groups. *Nat Rev Neurol*. 2022;18(5):307-314. doi:10.1038/s41582-022-00630-z

33.   Lee H, Tzuang M, Chow TW, et al. Translation and cultural adaptation of tools to assess diverse Asian American and Asian Canadian subgroups: The Asian Cohort for Alzheimer's Disease (ACAD) Study. *Alzheimer's & Dementia*. 2025;21(6). doi:10.1002/alz.70311

34.   Malik HB, Norman JB. Best practices and methodological strategies for addressing generalizability in neuropsychological assessment. *Journal of Pediatric Neuropsychology*. 2023;9(2):47-63. doi:10.1007/s40817-023-00145-5

35.   Kano F, Hirata S. Great Apes Make Anticipatory Looks Based on Long-Term Memory of Single Events. *Current Biology*. 2015;25(19):2513-2517. doi:10.1016/j.cub.2015.08.004

36.   Kano F, Tomonaga M. How chimpanzees look at pictures: a comparative eye-tracking study. *Proc R Soc B*. 2009;276(1664):1949-1955. doi:10.1098/rspb.2008.1811

37.   Wilson VAD, Zuberbühler K, Bickel B. The evolutionary origins of syntax: Event cognition in nonhuman primates. *Sci Adv*. 2022;8(25):eabn8464. doi:10.1126/sciadv.abn8464

38.   Werchan DM, Hume A, Zhang M, Vo T, Brito NH. From focus to function: Longitudinal insights into infant attention and emerging executive functions via remote webcam eye tracking. *Developmental Psychology*. 2025;61(5):957-963. doi:10.1037/dev0001948

39.   Horváth K, Hannon B, Ujma PP, Gombos F, Plunkett K. Memory in 3□month□old infants benefits from a short nap. *Developmental Science*. 2018;21(3):e12587. doi:10.1111/desc.12587

40.   Richmond JL, Zhao JL, Burns MA. What goes where? Eye tracking reveals spatial relational memory during infancy. *Journal of Experimental Child Psychology*. 2015;130:79-91. doi:10.1016/j.jecp.2014.09.013

41.   Sharma S, Kim H, Harris H, Haberstroh A, Wright HH, Rothermich K. Eye Tracking Measures for Studying Language Comprehension Deficits in Aphasia: A Systematic Search and Scoping Review. *J Speech Lang Hear Res*. 2021;64(3):1008-1022. doi:10.1044/2020_JSLHR-20-00287

42.   Proudfoot M, Menke RAL, Sharma R, et al. Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;17(1-2):101-111. doi:10.3109/21678421.2015.1054292

43.   Coe BC, Munoz DP. Mechanisms of saccade suppression revealed in the anti-saccade task. *Phil Trans R Soc B*. 2017;372(1718):20160192. doi:10.1098/rstb.2016.0192

44.   Munoz DP, Everling S. Look away: the anti-saccade task and the voluntary control of eye movement. *Nat Rev Neurosci*. 2004;5(3):218-228. doi:10.1038/nrn1345

45.   Manns JR, Stark CEL, Squire LR. The visual paired-comparison task as a measure of declarative memory. *Proc Natl Acad Sci USA*. 2000;97(22):12375-12379. doi:10.1073/pnas.220398097

46.   McDowell JE, Dyckman KA, Austin BP, Clementz BA. Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans. *Brain and Cognition*. 2008;68(3):255-270. doi:10.1016/j.bandc.2008.08.016

47.   Fernandez-Ruiz J, Peltsch A, Alahyane N, et al. Age related prefrontal compensatory mechanisms for inhibitory control in the antisaccade task. *NeuroImage*. 2018;165:92-101. doi:10.1016/j.neuroimage.2017.10.001

48.   Peltsch A, Hemraj A, Garcia A, Munoz DP. Age-related trends in saccade characteristics among the elderly. *Neurobiology of Aging*. 2011;32(4):669-679. doi:10.1016/j.neurobiolaging.2009.04.001

49.   Yep R, Smorenburg ML, Riek HC, et al. Interleaved Pro/Anti-saccade Behavior Across the Lifespan. *Front Aging Neurosci*. 2022;14:842549. doi:10.3389/fnagi.2022.842549

50.   Peltsch A, Hemraj A, Garcia A, Munoz DP. Saccade deficits in amnestic mild cognitive impairment resemble mild Alzheimer's disease. *Eur J of Neuroscience*. 2014;39(11):2000-2013. doi:10.1111/ejn.12617

51.   Riek HC, Brien DC, Coe BC, et al. Cognitive correlates of antisaccade behaviour across multiple neurodegenerative diseases. *Brain Communications*. 2023;5(2):fcad049. doi:10.1093/braincomms/fcad049

52.   Whitehead JC, Li L, McQuiggan DA, Gambino SA, Binns MA, Ryan JD. Portable eyetracking-based assessment of memory decline. *Journal of Clinical and Experimental Neuropsychology*. 2018;40(9):904-916. doi:10.1080/13803395.2018.1444737

53.   Crutcher MD, Calhoun-Haney R, Manzanares CM, Lah JJ, Levey AI, Zola SM. Eye Tracking During a Visual Paired Comparison Task as a Predictor of Early Dementia. *Am J Alzheimers Dis Other Demen*. 2009;24(3):258-266. doi:10.1177/1533317509332093

54.   Van Der Cruyssen I, Ben-Shakhar G, Pertzov Y, et al. The validation of online webcam-based eye-tracking: The replication of the cascade effect, the novelty preference, and the visual world paradigm. *Behav Res*. 2023;56(5):4836-4849. doi:10.3758/s13428-023-02221-2

55.   Hannula DE. Worth a glance: using eye movements to investigate the cognitive neuroscience of memory. *Front Hum Neurosci*. 2010;4. doi:10.3389/fnhum.2010.00166

56.   Zola SM, Manzanares CM, Clopton P, Lah JJ, Levey AI. A Behavioral Task Predicts Conversion to Mild Cognitive Impairment and Alzheimer's Disease. *Am J Alzheimers Dis Other Demen*. 2013;28(2):179-184. doi:10.1177/1533317512470484

57.   Pavey TG, Gomersall SR, Clark BK, Brown WJ. The validity of the GENEActiv wrist-worn accelerometer for measuring adult sedentary time in free living. *Journal of Science and Medicine in Sport*. 2016;19(5):395-399. doi:10.1016/j.jsams.2015.04.007

58.   Grill JD, Kwon J, Teylan MA, et al. Retention of Alzheimer Disease Research Participants. *Alzheimer Dis Assoc Disord*. 2019;33(4):299-306. doi:10.1097/WAD.0000000000000353

59.   Salazar CR, Ritchie M, Gillen DL, Grill JD. Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study. *JAD*. 2022;87(4):1557-1566. doi:10.3233/JAD-215537

60.   S0201: SELECTED POPULATION PROFILE ... - Census Bureau Table. Accessed July 25, 2024. https://data.census.gov/table/ACSSPP1Y2019.S0201?q=s0201&moe=false&hidePreview=true

61.   Government of Canada SC. The Daily — The Canadian census: A rich portrait of the country's religious and ethnocultural diversity. October 26, 2022. Accessed August 15, 2024. https://www150.statcan.gc.ca/n1/daily-quotidien/221026/dq221026b-eng.htm

62.   Babulal GM, Quiroz YT, Albensi BC, et al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. *Alzheimers Dement*. 2019;15(2):292-312. doi:10.1016/j.jalz.2018.09.009

63.   Dagley A, LaPoint M, Huijbers W, et al. Harvard Aging Brain Study: Dataset and accessibility. *Neuroimage*. 2017;144(Pt B):255-258. doi:10.1016/j.neuroimage.2015.03.069

64.   Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology*. 2010;74(3):201-209. doi:10.1212/WNL.0b013e3181cb3e25

65.   Sudre CH, Smith L, Atkinson D, et al. Cardiovascular Risk Factors and White Matter Hyperintensities: Difference in Susceptibility in South Asians Compared With Europeans. *J Am Heart Assoc*. 2018;7(21):e010533. doi:10.1161/JAHA.118.010533

66.   Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor? *Can J Cardiol*. 2006;22(3):193-197. doi:10.1016/s0828-282x(06)70895-9

67.   Kjeldsen EW, Frikke-Schmidt R. Causal cardiovascular risk factors for dementia: insights from observational and genetic studies. *Cardiovascular Research*. 2025;121(4):537-549. doi:10.1093/cvr/cvae235

68.   Qureshi D, Collister J, Allen NE, Kuźma E, Littlejohns T. Association between metabolic syndrome and risk of incident dementia in UK Biobank. *Alzheimer's & Dementia*. 2024;20(1):447-458. doi:10.1002/alz.13439

69.   Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. *Vasc Health Risk Manag*. 2008;4(2):363-381. doi:10.2147/vhrm.s1839

70.   Qiu SD, Zhang DD, Ma LY, et al. Associations of metabolic syndrome with risks of dementia and cognitive impairment: A systematic review and meta-analysis. *Journal of Alzheimer's Disease*. 2025;105(1):15-27. doi:10.1177/13872877251326553

71.   Alangh A, Chiu M, Shah BR. Rapid increase in diabetes incidence among Chinese Canadians between 1996 and 2005. *Diabetes Care*. 2013;36(10):3015-3017. doi:10.2337/dc13-0052

72.   Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. *Diabetes Care*. 2000;23(9):1353-1358. doi:10.2337/diacare.23.9.1353

73.   Robinson T, Klinger H, Buckley R, et al. Subjective cognitive decline across ethnoracial groups in the A4 study. *Alzheimers Dement*. 2023;19(9):4084-4093. doi:10.1002/alz.13138

74.   Ruthirakuhan M, Wood Alexander M, Cogo-Moreira H, et al. Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study. *The Journal of Prevention of Alzheimer's Disease*. 2024;11(1):48-55. doi:10.14283/jpad.2023.98

75.   Ho P, Yu WH, Tee BL, et al. Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non☐genetic risk factors for Alzheimer's disease among Asian Americans and Canadians. *Alzheimer's & Dementia*. Published online January 12, 2024:alz.13611. doi:10.1002/alz.13611

*References 1-12 below are cited in Table 2.

1. Ganzeboom HBG, Treiman DJ. Internationally Comparable Measures of Occupational Status for the 1988 International Standard Classification of Occupations. *Social Science Research*. 1996;25(3):201-239. doi:10.1006/ssre.1996.0010

2. Testa S, Doucerain MM, Miglietta A, Jurcik T, Ryder AG, Gattino S. The Vancouver Index of Acculturation (VIA): New evidence on dimensionality and measurement invariance across two cultural settings. *International Journal of Intercultural Relations*. 2019;71:60-71. doi:10.1016/j.ijintrel.2019.04.001

3. Craig CL, Marshall AL, Sj??Str??M M, et al. International Physical Activity Questionnaire: 12-Country Reliability and Validity: *Medicine & Science in Sports & Exercise*. 2003;35(8):1381-1395. doi:10.1249/01.MSS.0000078924.61453.FB

4. Prince SA, LeBlanc AG, Colley RC, Saunders TJ. Measurement of sedentary behaviour in population health surveys: a review and recommendations. *PeerJ*. 2017;5:e4130. doi:10.7717/peerj.4130

5. Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. *Clinical Gerontologist*. 1986;5(1-2):165-173. doi:10.1300/J018v05n01_09

6. Power M, Quinn K, Schmidt S, WHOQOL-OLD Group. Development of the WHOQOL-Old Module. *Qual Life Res*. 2005;14(10):2197-2214. doi:10.1007/s11136-005-7380-9

7. Chow CK, Lock K, Madhavan M, et al. Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries. Ross JS, ed. *PLoS ONE*. 2010;5(12):e14294. doi:10.1371/journal.pone.0014294

8. Williams DR, Yan Yu, Jackson JS, Anderson NB. Racial Differences in Physical and Mental Health: Socio-economic Status, Stress and Discrimination. *J Health Psychol*. 1997;2(3):335-351. doi:10.1177/135910539700200305

9. Carpenter JS, Andrykowski MA. Psychometric evaluation of the pittsburgh sleep quality index. *Journal of Psychosomatic Research*. 1998;45(1):5-13. doi:10.1016/S0022-3999(97)00298-5

10.   Walsh SP, Raman R, Jones KB, Aisen PS. ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI). *Alzheimer Disease & Associated Disorders*. 2006;20(Supplement 3):S170-S178. doi:10.1097/01.wad.0000213879.55547.57

11.   Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. *Neuropsychologia*. 2012;50(12):2880-2886. doi:10.1016/j.neuropsychologia.2012.08.011

12.   Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of Functional Activities in Older Adults in the Community. *Journal of Gerontology*. 1982;37(3):323-329. doi:10.1093/geronj/37.3.323

ACKNOWLEDGEMENTS

JSR receives support from the Harquail Centre for Neuromodulation, the Dr. Sandra Black Centre for Brain Resilience & Recovery, CIHR (173253), the Alzheimer Society of Canada Research Program, and the Alzheimer's Association (AARG☐23☐1144933). MG is supported by the Canada Research Chairs program (CRC-2021-00374), the Sandra Black Center for Brain Resilience and Recovery, and the Harquail Centre for Neuromodulation. SEB has received personal consulting fees from Roche, Biogen, Novo Nordisk, Eisai, and Eli Lilly. She also receives peer-reviewed research funding from the Ontario Brain Institute, Canadian Institutes of Health Research (CIHR), Leducq Foundation, Heart and Stroke Foundation of Canada, National Institutes of Health (NIH), Alzheimer's Drug Discovery Foundation, Brain Canada, Weston Brain Institute, and the Canadian Partnership for Stroke Recovery. She does not receive personal investigator fees from these funding sources. No other competing interests or funding sources were reported from the authors. We would like to thank Ms. Aastha Vaidya for her contribution to the CAMERA study.

FUNDING STATEMENT

The CAMERA study is supported by funding from the Alzheimer's Association (AARG-23-1144933), Alzheimer Society of Canada, and the Canadian Institutes of Health Research (CIHR) (173253).

CONSENT STATEMENT

The CAMERA study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre (SHSC) in Toronto, Canada. All participants provided informed consent.

Figure 1. CAMERA Timeline, Procedures, and Modalities

Figure 1 depicts the study timeline and procedures of the CAMERA study across the five-year study period. Participants complete in-person assessments at baseline (Year 1), Year 3 and Year 5, and complete questionnaires annually on REDCap.

Figure 2. CAMERA Eye-tracking Measures

Figure 2A depicts the Interleaved PRO/ANTI-Saccade Task (IPAST) and **2B** depicts the Visual

Paired Comparison Task (VPCT).

Table 1. CAMERA Neuropsychological Assessment Battery

Cognitive Domain	Tests
Global Cognition	Montreal Cognitive Assessment (MoCA) Clinical Dementia Rating (CDR) Scale
Processing Speed	Digit Symbol-Coding subtest from the Wechsler Adult Intelligence Scale (Third Edition) Trails Making Test (TMT) Part A Color Trails Test (CTT) I
Executive Function	N-Back Task (1-Back and 2-Back) Sustained Attention to Response Task (SART) Trails Making Test (TMT) Part B Color Trails Test (CTT) II Phonemic Fluency (FAS)
Visuoperceptual/ Visuospatial Processing	Four Choice Oddity Task Benson Complex Figure Test – Copy Trial
Learning and Memory	Free and Cued Selective Reminding Test (Form A) 7/24 Learning, Immediate Recall, and Delayed Recall (Form I) Benson Complex Figure Test – Delayed
Language	Category Fluency (Animals, Fruits, and Vegetables)
Pattern Separation	Doors and People Test (Doors Subtest) Mnemonic Similarity Task (MST – Set C)

Table 2. CAMERA Questionnaires

Variable	Data Collected and Questionnaires Administered
Demographic Information	Age Sex assigned at birth (male, female, intersex) Gender identity (man, woman, transgender man, transgender woman, non-binary, two-spirit) Handedness Sexual orientation Race Ethnicity Marital status and number of children Childhood and current household compositions Caregiver status
Socioeconomic Status	Education (number of years, location, and language) Self-reported household gross income Location of residence (urban/rural) Subjective rating of social status Employment status Occupation coded for prestige and cognitive complexity using the Standard Occupational Classification[1]
Immigration	Immigration status (country of origin, year entered Canada, and age at immigration) Ancestral country of origin Reason for immigration to Canada Age of immigration Year arrived in Canada Location of arrival Method of immigration Presence of social and community ties in Canada
Language	Native language Current primary language Age learned English Number of languages spoken
Acculturation	Vancouver Index of Acculturation[2] Acculturation Questionnaire
Medical History	Past and current chronic medical conditions Family health history of chronic medical conditions Current medications Birth history Learning/early attention difficulties Health status

Physical Activity	International Physical Activity Questionnaire (IPAQ)[3] International Sedentary Assessment Tool (ISAT)[4]

Vascular Risk	Cholesterol
	   Total cholesterol
	   Low-density lipoprotein (LDL) cholesterol
	   High-density lipoprotein (HDL) cholesterol
	   Non-HDL cholesterol
	Diabetes
	   HbA1c
	Hypertension
	   Systolic blood pressure
	   Diastolic blood pressure
	Waist-to-hip ratio

Mental Health	Geriatric Depression Scale (Long Form) (GDS-30)[5] Generalized Anxiety Disorder Scale (GAD-7) Behavioural Inhibition System (BIS) / Behavioural Activation System (BAS)
Quality of Life	World Health Organization Quality of Life Scale – Older Adults (WHOQOL-OLD)[6]
Community/Contextual Factors	Modified Environmental Profile of a Community's Health (EPOCH)[7]
Discrimination	Perceived Discrimination Scale (PDS)[8]
Sleep Quality	Pittsburgh Sleep Quality Index (PSQI)[9]
Cognitive Concerns	Cognitive Function Index (CFI) and CFI-Study Partner[10,11]
Functional Status	Functional Activities Questionnaire (FAQ) (informant-reported)[12]
Sex-Specific Questions	Female-specific health questions: Pregnancy history, menopausal history, menopausal symptoms, and current and past use of hormone therapy and hormonal contraceptives Male-specific health questions: Testosterone replacement therapy use, anabolic steroids use, and hormone-related conditions and treatments
All questionnaires are administered annually via REDCap.	

Table 3. Participant Demographic and Clinical Characteristics at Baseline (Year 1)

	Total Cohort	**South Asian**	**Chinese**	**Non-Hispanic White**	**Omnibus p-value**	**Post-hoc results** (FDR corrected)
N *(%)*	200	52 (26.0)	77 (38.5)	71 (35.5)	$p = 0.08$	NA
Age, *mean ± SD (years)*	67.3 ± 6.9	68.1 ± 7.6	68.0 ± 5.5	65.8 ± 7.4	$p = 0.06$	NA
Sex, *N (%) female*	136 (68.0)	38 (73.1)	47 (61.0)	51 (71.8)	$p = 0.25$	NA
Education, *mean ± SD (years)*	16.5 ± 2.3	16.9 ± 2.3	16.2 ± 2.1	16.6 ± 2.4	$p = 0.21$	NA
Annual Income[a], *N (%) $CAD*						
<$10,000 - $49,999	18 (9.0)	2 (3.8)	12 (15.8)	4 (5.6)	$p = 0.17$	NA
$50,000 - $149,999	71 (35.7)	17 (32.7)	30 (39.5)	24 (33.8)		
$150,000+	80 (40.2)	23 (44.2)	26 (34.2)	31 (43.7)		
Prefer not to disclose	30 (15.1)	10 (19.2)	8 (10.5)	12 (16.9)		
CFI Total Score[b], *mean ± SD*	2.0 ± 2.1	2.1 ± 2.3	2.6 ± 2.2	1.2 ± 1.5	$p < 0.001$	**SA > White, p = 0.04** **Chinese > White, p < 0.001** Chinese > SA, p = 0.13
GDS Total Score[b], *mean ± SD*	4.8 ± 4.8	4.8 ± 5.4	4.6 ± 4.1	5.0 ± 5.0	$p = 0.69$	NA
GAD-7 Total Score[b], *mean ± SD*	2.1 ± 3.1	2.3 ± 3.3	2.3 ± 3.5	1.7 ± 2.2	$p = 0.94$	NA
WHOQOL-OLD Total[b], *mean ± SD*	94.6 ± 11.8	93.5 ± 13.2	92.1 ± 10.8	98.0 ± 11.2	$p = 0.008$	SA < White, p = 0.09 **Chinese < White, p = 0.007** Chinese < SA, p = 0.78
Born in Canada, *N (%)*	64 (32.2)	1 (1.9)	10 (13.2)	53 (74.6)	$p < 0.001$	**SA < White, p < 0.001** **Chinese < White, p < 0.001** SA < Chinese, p = 0.06

Age at Immigration *mean ± SD*	26.6 ± 12.5	24.3 ± 9.2	29.9 ± 13.1	21.6 ± 15.8	$p = 0.02$	SA > White, p = 0.77 Chinese > White, p = 0.12 **Chinese > SA, p = 0.02**
English as a Second Language[*]**,** *N (%)*	125 (62.5)	40 (76.9)	68 (88.3)	17 (23.9)	$p < 0.001$	**SA > White, p < 0.001** **Chinese > White, p < 0.001** Chinese > SA, p = 0.14
Glucose Levels (HbA1c)[b] *mean ± SD (%)*	5.8 ± 0.5	5.8 ± 0.5	6.0 ± 0.5	5.5 ± 0.3	$p < 0.001$	**SA > White, p < 0.001** **Chinese > White, p < 0.001** SA < Chinese, p = 0.05
Total Cholesterol[c] *mean ± SD (mmol/L)*	5.2 ± 1.2	5.0 ± 1.3	5.1 ± 1.3	5.3 ± 1.1	$p = 0.34$	NA
HDL Cholesterol[c] *mean ± SD (mmol/L)*	1.7 ± 0.5	1.6 ± 0.4	1.8 ± 0.5	1.8 ± 0.5	$p = 0.009$	**SA < White, p = 0.02** Chinese vs White, p = 0.86 **SA < Chinese, p = 0.01**
LDL Cholesterol[c] *mean ± SD (mmol/L)*	2.9 ± 1.0	2.9 ± 1.1	2.8 ± 1.1	3.1 ± 0.9	$p = 0.32$	NA
Non-HDL Cholesterol[c] *mean ± SD (mmol/L)*	3.5 ± 1.1	3.5 ± 1.2	3.4 ± 1.2	3.5 ± 1.0	$p = 0.49$	NA
Triglycerides[c] *mean ± SD (mmol/L)*	1.1 ± 0.6	1.4 ± 0.7	1.1 ± 0.6	1.0 ± 0.5	$p = 0.004$*	**SA > White, p = 0.004** Chinese > White, p = 0.47 **SA > Chinese, p = 0.01**
Seated Systolic BP[b] *mean ± SD*	131.7 ± 16	133.4 ± 13.2	131.9 ± 16.3	130.2 ± 17.5	$p = 0.21$	NA
Seated Diastolic BP[b] *mean ± SD*	73.9 ± 9.0	72.5 ± 8.9	74.8 ± 9.2	73.8 ± 8.8	$p = 0.35$	NA
Waist-to-hip Ratio[d] *mean ± SD*	0.9 ± 0.1	0.9 ± 0.1	0.9 ± 0.1	0.9 ± 0.1	$p = 0.99$	NA

BMI[e] *mean ± SD (kg/m²)*	25.17 ± 4.23	25.8 ± 3.9	23.8 ± 3.8	26.2 ± 4.6	*p =* 0.001*	SA < White, p = 0.95 **Chinese < White, p = 0.003 Chinese < SA, p = 0.004**

Abbreviations: BMI: Body Mass Index; BP: Blood Pressure; CFI: Cognitive Function Instrument; GAD-7: Geriatric Anxiety Scale-7; GDS: Geriatric Depression Scale; HbA1c: Hemoglobin A1c; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; NA: Not Applicable; SA: South Asian; SD: Standard Deviation; WHOQOL-OLD: World Health Organization Quality of Life – Older Adults Module

[a]1 missing value; [b]2 missing values; [c]3 missing values; [d]4 missing values; [e]5 missing values
*Reported for participants who immigrated to Canada only
P-values represent results of ANOVA, Kruskal-Wallis, Chi-squared, or Fisher's Exact tests comparing groups.
Post-hoc results are reported for contrasts where p < 0.05.